Bay Island Cell, a biotech company founded by former Legend Biotech founder and chief scientist Xiaohu Fan, has completed a RMB 140 million Series A financing round led by Shenzhen Capital Group (SCGC), with participation from Orient Fortune Capital, according to 36Kr.
The report said GenScript, Legend Biotech's parent company, previously sued Fan over alleged trade secret infringement, but China's Supreme People's Court rejected all of GenScript's claims in a final ruling in late 2025. 36Kr also reported that Fan presented early human data at the American Society of Clinical Oncology (ASCO) annual meeting for Bay Island Cell's non-gene-editing allogeneic CAR-T platform in diffuse large B-cell lymphoma, and the company has started a new fundraising round to support upcoming clinical trials.
Cell Therapy Startup Bay Island Cell Raises RMB 140 Million in Series A
2026-07-10 08:42:28
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
高盛：预计南非央行7月维持利率不变
